Stock Analysis

908 Devices Full Year 2022 Earnings: EPS Misses Expectations

Published
NasdaqGM:MASS
Source: Shutterstock

908 Devices (NASDAQ:MASS) Full Year 2022 Results

Key Financial Results

  • Revenue: US$46.9m (up 11% from FY 2021).
  • Net loss: US$33.6m (loss widened by 51% from FY 2021).
  • US$1.07 loss per share (further deteriorated from US$0.79 loss in FY 2021).
earnings-and-revenue-growth
NasdaqGM:MASS Earnings and Revenue Growth March 17th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

908 Devices EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.5%.

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Electronic industry in the US.

Performance of the American Electronic industry.

The company's shares are up 7.6% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 3 warning signs for 908 Devices you should know about.

What are the risks and opportunities for 908 Devices?

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.

View Full Analysis

Rewards

  • Revenue is forecast to grow 17.97% per year

Risks

  • Shareholders have been diluted in the past year

  • Volatile share price over the past 3 months

  • Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report

About NasdaqGM:MASS

908 Devices

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets.

Excellent balance sheet and overvalued.